0:00
Hello. My name's Ashley Birkett.
I'm the Director of PATH
Malaria Vaccine Initiative.
And I'm going to give
you an update today
on current progress in malaria
vaccine development efforts.
0:11
The presentation that
I'm going to give
is really divided into
two main sections.
First, introduction. I'm going to
go through the burden of disease
and recent trends in malaria
morbidity and mortality,
review the malaria life cycle
and the vaccine opportunities
that that provides,
the biological evidence
to support vaccine approaches.
It's extremely important that
we have evidence that it is
possible to induce immunity
and to support vaccine
development efforts in humans.
And then I'm going to switch over
to vaccine development review,
the current community
goals with you,
what the current targets
are for vaccine development,
the type of vaccines we're trying to
develop, and the target efficacies.
Efforts to increase the probability
of success in reducing risks
as we develop these products, and
then the current progress
against the malaria vaccine
technology roadmap goals.
Those are the community goals.
And I'll review the goals and the
current progress in achieving them.
The introduction will come first.
1:08
This slide here gives you
estimated spatial distribution
of Plasmodium falciparum malaria
around the world in 2010.
Malaria in humans is caused by
two main parasites, Plasmodium
falciparum, which is
responsible for most
of the deaths around the
world, and Plasmodium vivax.
So as you can see
from this slide here,
the red areas indicate the areas
of very high and intense malaria
transmission.
This is where you would
see most of the cases.
So clearly, West Africa is really a
hotbed of falciparum transmission.
And then the blue
areas indicate more
moderate levels of transmission.
But you can see it's extremely
widespread around the world
And close to 100 countries
in total populations
are infected with malaria.
